Education
About Us
Working with TipRanks
Follow Us
Passage Bio (PASG)
NASDAQ:PASG
Total Valuation
Passage Bio has a market cap or net worth of $26.95M. The enterprise value is $4.41M.
Market Cap$26.95M
Enterprise Value$4.41M
Share Statistics
Passage Bio has 3,207,810 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding3,207,810
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Passage Bio’s return on equity (ROE) is -2.43 and return on invested capital (ROIC) is -100.90%.
Return on Equity (ROE)-2.43
Return on Assets (ROA)-0.73
Return on Invested Capital (ROIC)-100.90%
Return on Capital Employed (ROCE)-1.10
Revenue Per Employee0.00
Profits Per Employee-758.70K
Employee Count60
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Passage Bio is ―. Passage Bio’s PEG ratio is 0.02.
PE Ratio―
PS Ratio0.00
PB Ratio2.00
Price to Fair Value2.00
Price to FCF-1.19
Price to Operating Cash Flow-0.85
PEG Ratio0.02
Income Statement
In the last 12 months, Passage Bio had revenue of 0.00 and earned -45.52M in profits. Earnings per share was -14.35.
Revenue0.00
Gross Profit-728.00K
Operating Income-43.15M
Pretax Income-45.52M
Net Income-45.52M
EBITDA-44.66M
Earnings Per Share (EPS)-14.35
Cash Flow
In the last 12 months, operating cash flow was -31.51M and capital expenditures 0.00, giving a free cash flow of -31.51M billion.
Operating Cash Flow-31.51M
Free Cash Flow-31.51M
Free Cash Flow per Share-9.82
Dividends & Yields
Passage Bio pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.98
52-Week Price Change2.94%
50-Day Moving Average11.41
200-Day Moving Average8.63
Relative Strength Index (RSI)40.96
Average Volume (3m)41.18K
Important Dates
Passage Bio upcoming earnings date is May 19, 2026, Before Open (Confirmed).
Last Earnings DateMar 3, 2026
Next Earnings DateMay 19, 2026
Ex-Dividend Date―
Financial Position
Passage Bio as a current ratio of 2.07, with Debt / Equity ratio of 128.02%
Current Ratio2.07
Quick Ratio2.07
Debt to Market Cap0.64
Net Debt to EBITDA0.50
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Passage Bio has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Passage Bio EV to EBITDA ratio is -0.34, with an EV/FCF ratio of -0.48.
EV to Sales0.00
EV to EBITDA-0.34
EV to Free Cash Flow-0.48
EV to Operating Cash Flow-0.48
Balance Sheet
Passage Bio has $46.30M in cash and marketable securities with $24.01M in debt, giving a net cash position of $22.29M billion.
Cash & Marketable Securities$46.30M
Total Debt$24.01M
Net Cash$22.29M
Net Cash Per Share$6.95
Tangible Book Value Per Share$5.91
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Passage Bio is $25.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$25.33
Price Target Upside201.55% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast―
EPS Growth Forecast38.42%